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ABSTRACT
Objective To describe the factors that contributed to
successful recruitment of more than 200000 women to
the UK Collaborative Trial of Ovarian Cancer Screening,
one of the largest ever randomised controlled trials.
Design Descriptive study.
Setting 13 NHS trusts in England, Wales, and Northern
Ireland.
Participants Postmenopausal women aged 50-74;
exclusion criteria included ovarian malignancy, bilateral
oophorectomy, increased risk of familial ovarian cancer,
active non-ovarian malignancy, and participation in other
ovarian cancer screening trials.
Main outcome measures Achievement of target
recruitment, acceptance rates of invitation, and
recruitment rates.
Results The trialwas set up in13centreswith27adjoining
local health authorities. The coordinating centre teamwas
led by one of the senior investigators, who was closely
involved in planning and day to day trial management. Of
1243282 women invited, 23.2% (288955) replied that
they were eligible and would like to participate. Of those
sent appointments, 73.6% (205090) attended for
recruitment. The acceptance rate varied from 19% to 33%
between trial centres. Measures to ensure target
recruitment included named coordinating centre staff
supporting and monitoring each centre, prompt
identification and resolution of logistic problems, varying
the volume of invitations by centre, using local non-
attendance rates to determine the size of recruitment
clinics, and organising large ad hoc clinics supported by
coordinating centre staff. The trial randomised 202638
women in 4.3 years.
Conclusions Planning and trial management are as
important as trial design and require equal attention from
senior investigators. Successful recruitment needs
constant monitoring by a committed proactive
management team that is willing to explore individual
solutions for different centres anduse central resources to
improve local recruitment. Automation of trial processes
with web based trial management systems is crucial in
large multicentre randomised controlled trials.
Recruitment canbe further enhancedbyusing information
videos and group discussions.
Trial registration Current Controlled Trials
ISRCTN22488978.
INTRODUCTION
Randomised controlled trials are widely accepted as
the standard for evaluating healthcare interventions.
However, only 31% of multicentre randomised con-
trolled trials funded by the UK Medical Research
Council and the NHSHealth Technology Assessment
Programme that were recruiting between 1994 and
2002 achieved their original recruitment target.1 This
has important implications for allocation of resources,
lost opportunity for trials that fail to complete, and loss
of statistical power for completed trials.2
Although the design and scientific validity of
randomised controlled trials have been subject to
intense scrutiny, themanagement and conduct of these
trials receive limited attention. Large multicentre
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randomised controlled trials, like other complex
organisational ventures, needmeticulousmanagement
if they are to be successful.Many fail to deliver because
of the lack of a practical professional approach to
getting the job done.3 Furthermore, in randomised
controlled trials involving screening and prevention,
having to invite large numbers of potential participants
is an additional challenge.4
In 2000 expertise accumulated over a decade of
planning and running ovarian cancer screening trials
was used to design and set up the UK Collaborative
TrialofOvarianCancerScreening (UKCTOCS;www.
ukctocs.org.uk).5-9 Recruitment of the required target
of 202 638 women was completed in 2005, making it
one of the largest ever randomised controlled trials.
This report describes the approach to planning and
management that contributed to successful recruit-
ment.
METHODS
The UKCTOCS is a randomised controlled trial
aiming to assess the impact of screening on mortality
from ovarian cancer while comprehensively evaluat-
ing performance characteristics of the screening
strategies, physical and psychological morbidity,
compliance, and cost. The design involves 200 000
women randomised to annual screening with serum
CA 125 or transvaginal ultrasound or no intervention
(fig 1). The inclusion criteria were women aged 50-74
and with postmenopausal status; the exclusion criteria
were bilateral oophorectomy, previous ovarian malig-
nancy, increased risk of familial ovarian cancer, active
non-ovarian malignancy, and participation in other
ovarian cancer screening trials.
A senior investigator leads trial management based
at the coordinating centre. We use a custom built, web
based trial management system to centralise and
automate trial processes. We identified NHS trusts
(trial centres)wishing toparticipate and set themup in a
staggered fashion over the course of two years.
Recruitment started at a trial centre when at least
1500 local women had accepted the invitation. The
launch of the trial was accompanied by national media
coverage.Thiswas followedby localmedia coverage in
the form of radio interviews and newspaper articles as
each centre started recruitment. We briefed the staff
manning the telephone lines of the patient support
charities OVACOME and Cancer BACUP and
provided them with answers to frequently asked
questions before any publicity.
Control
group
(n=100 000)
Ultrasound group
Annual TVS
(n=50 000)
Multimodal group
Annual CA125-ROCA
(n=50 000)
Postmenopausal women 50-74 years (n=200 000)
All women followed up through Office for National Statistics
(England and Wales)/Cancer Registry and Central Services
Agency (Northern Ireland) as well as postal questionnaires
Screening until 31 December 2011;
7-11 annual screens
Primary end point:
ovarian cancer
mortality by
31 December 2014
Fig 1 | Trial design of UK Collaborative Trial of Ovarian Cancer
Screening. ROCA=risk of ovarian cancer algorithm;
TVS=transvaginal scan
Acceptance and recruitment rates at each regional centre
Regional centre Invited Accepted
Reported they
were ineligible*
Acceptance
rate† (%)
No
randomised
No of active
years
No randomised
per week
Manchester 133 584 26 027 8 939 20.9 16 504 3.3 114
Derby 65 391 19 688 5 093 32.7 14 920 3.0 113
Cardiff 96 633 23 890 8 754 27.2 16 756 3.4 112
Portsmouth 95 004 27 462 8 743 31.8 19 182 4.0 109
East London (Bart’s) 167 419 30 047 10 273 19.1 19 944 4.2 108
North Wales 73 956 21 299 5 144 31.0 14 326 3.3 99
North London (Royal Free) 133 572 24 391 6 416 19.2 16 737 3.9 98
Bristol 75 016 22 863 5 706 33.0 16 550 3.9 96
Nottingham 77 052 21 906 7 001 31.3 16 779 4.2 91
Gateshead 109 026 24 635
8 882 22.9 17 323 4.4 89
Gateshead (PCT invited)‡ 13 000 1 323
Middlesbrough 52 832 13 569 3 274 27.4 9 926 2.6 87
Belfast (PCT invited)‡ 86 810 16 962 NA 19.5 13 579 3.6 86
Liverpool (PCT invited)‡ 63 987 14 893 NA 23.3 10 112 4.0 57
Overall 1 243 282 288 955 NA 24.8 202 638 47.8 96
Overall excluding
Gateshead, Belfast and
Liverpool PCT invited
1 079 485 255 777 78 225 25.5 NA NA NA
NA=not applicable; PCT=primary care trust.
*Data incomplete as unknown proportion of ineligible women did not reply.
†Ineligible women not included in numerator or denominator.
‡Only eligible women replied owing to manner in which invitations were sent,.
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Invitation
We sent information about the trial to all general
practitioners working in participating primary care
trusts, after electronic upload of their details into the
trialmanagement system.We requestedelectronic files
containing details of 2000 to 10 000 women on a
regular (usually three monthly) basis from each of the
participating primary care trusts for upload. We then
sent women personal invitations and logged replies on
the trial management system (fig 2). The patient
support groups OVACOME and Cancer BACUP
vetted the information for patients, and invitation
letters contained their contact details. In the course of
the trial, we revised and simplified the invitation.
Recruitment and randomisation
We set the weekly recruitment target at 100 women per
trial centre.We set up individual profiles comprising five
recruitment clinics a week on the trial management
system foreach trial centre.These consistedof 45minute
appointments involving groups of four women. Once
acceptance was logged, women were automatically
scheduled into the appointment slots at the centre and
sent letters. The web browser enabled immediate
logging of clinic attendance as well as rescheduling of
appointments by both local and coordinating centre
staff. At recruitment, women viewed an information
video and participated in a group discussion. This was
immediately followed by a one to one discussion in a
separate room with the research nurse, when women
were given the opportunity to discuss any private
concernsbefore signing consent.Thenurse also checked
their completed datasheet. These documents were sent
weekly to the coordinating centre, where the trial
management systemautomatically confirmedeligibility,
did randomisation, scheduledappropriateappointments
to women allocated to screening, and printed letters to
the patient and her general practitioner (fig 2). We sent
requests for more information to women with incom-
plete data and placed “on hold” those whose last
menstrual period was less than 12 months from date of
recruitment. The trialmanagement system also classifies
screening results (ultrasound findings and CA 125
concentrations) enteredover thewebbrowser, schedules
appropriate follow-up appointments, and prints all
letters to individual women. It allows electronic
exchange of information with the CA 125 analyser in
the laboratory andwith theOffice forNational Statistics.
We loggedandmonitoredall complaints centrally.A
designated person at the coordinating centre wrote to
each woman directly after investigating the problems
raised.We explored all suggestions by the women and
amended trial logistics when appropriate and possible.
RESULTS
Between April 2001 and February 2003 we set up the
trial in 13 NHS trusts (trial centres) in England,Wales,
and Northern Ireland (table). A variety of logistical
reasons (lack of space, retirement of potential research
leads, unwillingness of trusts’ management to commit
to a 10 year trial, involvement in other ovarian cancer
screening trials) prevented pre-identified Scottish
centres from participating. Overall, 27 primary care
trusts (including local health boards in Wales) with
3266 general practices were involved. Of these, 22
(81.5%) primary care trusts provided contact details of
the women, and we sent invitations as outlined above.
Five (18.5%) primary care trusts (those adjoining the
centres at Liverpool, Belfast, and initially Gateshead)
refused access to the contact details. For these trusts, we
negotiated an alternative method using “unlinked”
invitations. This involved sending the standard invita-
tion letter without a recipient’s name to the primary
care trust in sealed franked envelopes. Trust staff then
attached address labels and forwarded the letters.
Women who wished to participate wrote to the
coordinating centre with their contact details (fig 2).
We modified trial processes and the trial management
system to allow manual entry of these data.
Invitation
We closely monitored acceptance rates from the start
and therefore noted within the first six months that
recruitment was below target. We rapidly introduced
Invitation  
(B) Invitation letter with no name together with
datasheet for entry of personal details sent
in sealed franked envelopes to local HA
Invitation  
Personal invitations printed and
posted from coordinating centre
(A) File with personal information of women
provided by local health authority (HA)
uploaded on to TMS
TMS schedules appointment at recruitment clinic at appropriate
centre and prints letters, which are sent out from coordinating centre
Consent logged and recruitment datasheet scanned into TMS
Recruitment visit
Seven minute information video
Group discussion facilitated by research nurse 
Completion of datasheet 
Five minute interview with research nurse
when baseline datasheet checked and consent signed
Blood sample
(transported overnight to central laboratory)
Replies logged on TMS
Randomisation by TMS
Control group
No screening
Multimodal group
Screening with serum CA125
Ultrasound group
Screening with transvaginal scan
Address labels pasted by
local HA staff and posted
Replies with personal details entered into TMS
Eligibility confirmed Incomplete datasheet or ineligible
Women placed “on hold” and
letters sent for clarification
Weekly transfer of documents to coordinating centre
Fig 2 | Invitation, recruitment, and randomisation. (A)=recruitment in which primary care trusts
(PCTs) were allowed access to contact details of women; (B)=recruitment in which PCTs did not
allow access to contact details of women; TMS=trial management system
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measures (listed below) to improve rates of acceptance
of the invitation. Overall, invitations were sent to
1 243 282 women, 1 079 485 directly by the coordinat-
ing centre and 163 797 by the primary care trusts
adjoining the centres at Liverpool, Belfast, and initially
Gateshead; 288 955 (23.2%) women replied that they
would like to participate in the trial and were eligible.
The overall acceptance rate varied between centres
from 19% in East London to 33% in Bristol (table).
Recruitment and randomisation
Between April 2001 and September 2005 205 090
women (73.6% of those who were sent appointments)
attended for recruitment, and we finally randomised
202 638 women (fig 3). The number of women
randomised each month ranged from 117 to 5773
(median 3955)10; the median time from recruitment to
randomisationwas 12.3days (25th to 75th centile 8.5 to
15.5 days).
A further 10 192womenwho accepted the invitation
were not sent appointments as the recruitment target
was achieved.With ethics committee approval,we sent
a letter to thank each woman for her interest in the trial
and apologise for our inability to offer her a place as the
target recruitment had been reached.
Overall recruitment was 96% (range 87-114%) of the
weekly target of 100women. Five centres exceeded the
weekly target (table). The centres using “unlinked
invitations” had some of the lowest recruitment rates.
The box details the measures we adopted to ensure
target recruitment. Ninety eight (0.008%) invited
women complained about recruitment related pro-
blems: invitation to trial (32), trial information (28),
recruitment appointment (17), and randomisation to
control group (21).
DISCUSSION
Our experience highlights the importance of meticu-
lous planning and management of trial processes.
These are as crucial to success as trial design and
require equal attention from senior investigators. We
quickly learnt that thekey to successful recruitmentwas
constantmonitoringbyadedicatedmanagement team,
capable of delivering flexible and rapid solutions as
problems arose. Centralisation and automation of trial
processes with web based trial management systems
were crucial. Informationvideos andgroupdiscussions
facilitated recruitment and helped to maintain quality.
The revisionof theUKCTOCS invitationprocedure
provides an example of the flexibility needed in
running trials. Although most (81.5%) local health
authority data controllers allowed access to women’s
contact details under the research exemption clause of
the Data Protection Act 1998 (www.informationcom
missioner.gov.uk), 18.5% (n=5) refused permission.
We found a compromise to accommodate their
concerns and revised the entire invitation process,
including functionality of the trial management system
and the job description of administrative staff at the
coordinating centre. Excluding these health authorities
would have required suspension of the trial in the
adjoining centres, with a major impact on recruitment
rates, time, and resources.
Strengths and weaknesses
We invited women from participating local health
authorities’ registers. This is an approach often used in
the United Kingdom.11 12 Other databases in use
include electoral rolls, driving licence records, and
commercially available directories.13 The alternative
strategy is to advertise the trial extensively and let
participants self refer.14 Recently, this has involved
Google adverts and links to studies on a variety of
websites.15 Women who volunteer to participate in
research are often more educated and informed than
the general population.16-18 Hence, invitation using
health authority lists or electoral rolls is thought to
result in participants who are more representative of
the general population than those who self refer
through adverts. Use of health authority lists provides
additional logistical advantages. Recruitment rates can
be controlled by varying the volume and frequency of
mailing invitations, and electronic data transfer from
health authority files leads to decreased data entry and
improved accuracy. This is particularly notable with
regard to NHS numbers, which are essential for cost
effective follow-up of women through the UK Office
for National Statistics. In a previous trial, in which
women self referred, most women did not provide an
NHS number.19 Finally, mass mailing allows accep-
tance rates and their variation between centres to be
determined.
Recruitment rates vary with time and between
centres. Maintaining this at target levels requires
constant monitoring and individual solutions, as
problems differ between centres. Support from the
Contact details of women received as electronic file from PCT and loaded on to TMS (n=1 084 632)
Women sent invitations from CC (n=1 079 485)
Excluded (n=2452):
  Did not meet inclusion criteria (n=1402)
  Refused to participate (n=292)
  Other reasons (n=758)
Did not
reply
(n=647 007)
Decided not
to join
(n=98 476)
Ineligible at
invitation
(n=78 225)
Not recruited as target
reached (n=10 192) 
Withdrew from
study (n=73 673)
Women sent invitations by PCTs (n=163 797)
Accepted  (n=288 955)
Women not sent invitations (n=5147)
Attended recruitment (n=205 090)
Randomisation (n=202 638)
Allocation
Enrolment
Ultrasound group (n=50 639)Multimodal group (n=50 640)Control group (n=101 359)
33 178 255 777
Fig 3 | Flow diagram of progress through recruitment phase of UK Collaborative Trial of Ovarian
Cancer Screening. CC=coordinating centre; PCT=primary care trust; TMS=trial management
system
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relevant patients’ support groups is crucial. For trials
with lower acceptance rates, one solution is to increase
the volume and frequency ofmailing of invitations and
local media coverage. Mass broadcast (television and
radio) and print media are “low effort, high yield”
recruitment strategies.20 21 In the UKCTOCS, as
participation was limited to invited women, we were
constantly trying to find the balance between toomuch
and too little publicity. To this end, we avoided posters
and flyers in general practitioners’ surgeries, well
women clinics, and so on. Such publicity may have
persuaded more women to take up their invitation.
InFLEXISIG, the sigmoidoscopy screening trial, the
involved general practices checked the local authority
lists and excluded 2% of 375 744 men and women as
they were deemed ineligible owing to colorectal
cancer, terminal disease, and so on.22 In the
UKCTOCS, the3266generalpracticesdidnocleaning
of lists, as we were concerned that this would affect
timely mailing of invitations, which was crucial to
maintain target recruitment. Thirty two of 1.2 million
women invited complained about being contacted.
This included four women with ovarian cancer out of
an estimated 587 who would have been invited on the
basis of national incidences.23Given the small numbers
excluded in FLEXISIG, the low rate of complaints in
the UKCTOCS, and the substantial effort required,
“cleaningup”of local authority lists doesnot seem tobe
necessary.
The overall acceptance rate was one in four (23%).
However, the ratesvariedbetweendifferentparts of the
country. The data suggest that in cities such as London,
Manchester, and Belfast one should expect lower
acceptance rates in the rangeof one in five.However, in
other parts of the country, such as Nottingham,
Portsmouth, Bristol, and Derby, almost one in three
women in the 50-74 age group might accept an
invitation toparticipate ina screening trial.Thevarying
uptake highlights the importance of running pilots at
multiple centres. The UKCTOCS data are being
analysed to see whether acceptance rates can be
estimated by using age and the postcode derived
index for multiple deprivation.
We could not account for undelivered invitations in
our trial, as the initial invitations were posted in
envelopes with no return address. In the recent
FLEXISIG trial, 4% of invitations were undelivered,12
and this is useful in calculating accurate acceptance
rates. The overall acceptance rate in the UKCTOCS
was similar to that seen in the colorectal cancer
screening trial at Dundee and the WISDOM trial
involving oestrogen use after themenopause.2425 These
rates were substantially higher than the 4.3% accep-
tance rate reportedafter amassmailingofmore than3.4
million in the US systolic hypertension (SHEP) trial.13
However, theyweremuch lower than the55%achieved
in the UK FLEXISIG trial. One reason is the way
randomisationwas approached. In theUKCTOCS,we
asked women to help to test a new screening
programme for ovarian cancer. We told them that we
would need to involve 200 000 women, half of whom
would be screened and half would have the usual
medical care. In FLEXISIG, participants were asked,
“If youwere invited to have the bowel cancer screening
test, would you take up the offer?” The acceptance rate
was based on those who answered “yes.”22 This
emphasises the importance of wording of the invita-
tions, an aspect sometimes overlooked in clinical trials.
Meta-analysis ofbreast screening trials shows thatuseof
direct contact strategies involving telephone or any
type of personal contact can also significantly increase
uptake. However, this is only feasible in smaller trials,
and concerns about the cost effectiveness have been
expressed.26 Another way to improve acceptance rates
in screening trials is to invite people who regularly
attend established screening programmes such as
breast and cervical cancer screening, as they are self
selected for their belief in screening.27 In the Million
Women Study, 71% of women having breast screening
returned the studyquestionnaire comparedwith53%of
all those invited.28 This was not possible in the
Strategies adopted to facilitate recruitment
Set-up
 Custom built trial management system to centralise and automate all trial processes
such as invitation, logging of replies, scheduling of appointments, confirmation of
eligibility, randomisation, and printing of letters
 Webbrowserandhighsecurityencryptionenablingstaffatall locations toenterandview
data and reschedule appointments
 Specialised software commissioned from theNHS to flagwomenonprimary care trusts’
registers and allow electronic transfer of their personal and general practice details to
the coordinating centre in lots of 5000 to 10000 every quarter
 Trial website (www.ukctocs.org) for use by lay people and health professionals
Invitation
 Support of relevant patients’ groups/charities
 National and local media coverage
 Mass mailing of invitations from coordinating centre
 Personal invitation with tear-off reply slip and prepaid return envelopes
 Accompanyingbrochuredescribing thegoalsand requirementsof the trial in simpleand
concise terms
 Regular monitoring of acceptance rates to establish frequency and volume of mailing
needed
Recruitment
 Ensuring adequate numbers of women have accepted the invitation before starting
recruitment at a trial centre
 Increasing appointments in individual recruitment clinics to accommodate low
attendance
 Additional large ad hoc clinics staffed by both local and coordinating centre teams
 Information video at recruitment appointment
 Interactive group discussions
Management by coordinating centre
 Senior investigator involved in day to day running of trial
 Proactive management team
 Named coordinating centre member interacting with each trial centre on a daily basis
 Prompt identification and resolution of logistical problems (staffing, delivery of
consumables, information technology networking problems, postal strikes)
 Fortnightly monitoring of targets
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UKCTOCS, as these programmes are limited to
women aged below 65 in the UK.
In the UKCTOCS, 202 638 women were rando-
mised in 4.3 years, which translates to a randomisation
rate of 47 125 per year. The only trial to report higher
rates was the FLEXISIG trial, with a randomisation
rate of 68 173 per year.12 This was achieved by
adopting a two stage recruitment design; 170 483
people who agreed to attend bowel cancer screening
if invited were randomised, and only 40 674 allocated
to the screen arm were recruited.29 This design,
however, does mean that only limited data and no
biological samples are available in the control group. In
addition, recent revisions of laws such as the Data
ProtectionAct and theMentalCapacityActmight lead
to difficulties in follow-up through the Office for
National Statistics and use of data in secondary studies.
None the less, postal recruitmentwith attendance at the
clinic only for people randomised to the study arm is an
attractive design with significant savings in terms of
time and resources and is definitely worth exploring.
Sophisticated web based trial management systems
are becoming the norm for multicentre clinical
trials.29 30 They enable simultaneous data entry from
multiple sites by using standard web browsers with
centralised data processing. In large multicentre
screening trials such as the UKCTOCS, such technol-
ogy ensures strict adherence to the protocol over a long
period of time. Such solutions can be prohibitively
expensive, however, especially for individual research
groups. A move to encourage research and funding
organisations to combine efforts to produce an open
source solution for management of trial data is now
occurring. This would empower a wider variety of
people to do trials and may encourage more investi-
gators in resource poor settings to take part in high
standard research.31
A novel feature of the UKCTOCS was the use of an
informationvideo andgroupdiscussionduring recruit-
ment. The video ensured that all participants received
high quality standardised information which was
sustainable. Research nurses recruiting an average of
100 women a week find it difficult to deliver the same
highqualitymessage repeatedly.Thevideoalsohelped
with retention of experienced staff by relieving the
monotonyof repeating the samemessagemany times a
day over four years of recruitment. The group
discussions often generated queries that helped volun-
teers to arrive at a more educated and informed
decision than might have been possible if they were
only seen individually in a busy recruitment clinic.
One in 6.5 women aged 50-74 in England, Wales,
andNorthern Ireland (total population8 031 463)were
invited to participate in the UKCTOCS.32 This is a
major strength, as itmakes extrapolationof the findings
relevant to people planning randomised controlled
trials in theUK.However, the population is not wholly
representative of the UK, as the pre-identified Scottish
centres were unable to participate.
Implications of the study
Running large multicentre trials is challenging. Senior
investigators need to set aside time to support day to
day trial management. Centralisation and automation
of trial processes by use ofwebbased trialmanagement
systems with high security encryption are essential.
Information videos and group discussions allow
sustained delivery of high quality standardised infor-
mation during prolonged recruitment. The over-riding
approach needs to be one that incorporates proactive
management, flexibility, and individualised solutions.
Close cooperation and regular communication
between the coordinating and trial centre teams are
key to success.
We are particularly grateful to the women throughout the UK who are
participating in the trial and to the entire medical, nursing, and
administrative staff who work on the UKCTOCS.
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